We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

138 hedge funds and large institutions have $2.15B invested in Protagonist Therapeutics in 2021 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 60 increasing their positions, 36 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 5 → 10 (+5)

88% more capital invested

Capital invested by funds: $1.15B → $2.15B (+$1B)

73% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 15

67% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 36

9% more funds holding

Funds holding: 127 → 138 (+11)

1.29% more ownership

Funds ownership: 101.2% → 102.48% (+1.3%)

53% less call options, than puts

Call options by funds: $1.11M | Put options by funds: $2.35M

Holders
138
Holders Change
+11
Holders Change %
+8.66%
% of All Funds
2.4%
Holding in Top 10
10
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+100%
% of All Funds
0.17%
New
26
Increased
60
Reduced
36
Closed
15
Calls
$1.11M
Puts
$2.35M
Net Calls
-$1.24M
Net Calls Change
-$926K

Top Buyers

1
Victory Capital Management
Victory Capital Management
Texas
+$27.9M
2
Deutsche Bank
Deutsche Bank
Germany
+$26.3M
3
CCM
Consonance Capital Management
New York
+$24.3M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$18M
5
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
+$17.7M

Top Sellers

1
BBA
Baker Bros. Advisors
New York
-$32.4M
2
NHAS
Novo Holdings A/S
Denmark
-$8.84M
3
State Street
State Street
Massachusetts
-$8.52M
4
SI
Sofinnova Investments
California
-$6.79M
5
BI
BVF Inc
California
-$6.78M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$319M +$18M +545,156 +8%
BI
2
BVF Inc
California
$168M -$6.78M -205,356 -5%
RI
3
RTW Investments
New York
$157M – – –
CCM
4
Consonance Capital Management
New York
$155M +$24.3M +737,165 +27%
BlackRock
5
BlackRock
New York
$136M +$1.28M +38,912 +1%
JJIJ
6
Johnson & Johnson Innovation - JJDC
New Jersey
$110M – – –
FCM
7
Farallon Capital Management
California
$105M -$3.15M -95,320 -4%
Vanguard Group
8
Vanguard Group
Pennsylvania
$103M +$4.87M +147,487 +7%
State Street
9
State Street
Massachusetts
$65.3M -$8.52M -258,063 -15%
DM
10
Deerfield Management
New York
$61.2M +$3.43M +104,000 +8%
Point72 Asset Management
11
Point72 Asset Management
Connecticut
$51.8M +$7.03M +212,900 +23%
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$44.3M +$2.4M +72,664 +8%
Victory Capital Management
13
Victory Capital Management
Texas
$37.9M +$27.9M +845,199 New
Deutsche Bank
14
Deutsche Bank
Germany
$36.9M +$26.3M +796,161 +3,115%
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$35.5M +$4.45M +134,915 +21%
OWP
16
Obermeyer Wealth Partners
Colorado
$34.2M +$12.4M +374,946 +97%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$32M +$2.25M +68,159 +11%
NHAS
18
Novo Holdings A/S
Denmark
$26.9M -$8.84M -267,714 -31%
Adage Capital Partners
19
Adage Capital Partners
Massachusetts
$24.7M -$1.65M -50,000 -8%
Loomis, Sayles & Company
20
Loomis, Sayles & Company
Massachusetts
$24.1M +$17.7M +536,920 New
BBA
21
Baker Bros. Advisors
New York
$20.4M -$32.4M -980,916 -68%
SI
22
Sofinnova Investments
California
$20.2M -$6.79M -205,818 -31%
Northern Trust
23
Northern Trust
Illinois
$20M +$960K +29,072 +7%
JP Morgan Chase
24
JP Morgan Chase
New York
$19.5M -$5M -151,469 -26%
Citadel Advisors
25
Citadel Advisors
Florida
$18.1M +$6.77M +204,990 +103%
1
2 3 4 5

PTGX Hedge Fund Activity: Q2 2021 in Review

138 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2021, worth a combined $2.15B — up 88% from $1.15B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new PTGX positions and 15 closed out — a net gain of 11 holders — while 60 added to existing stakes and 36 trimmed.

The largest buyer was Victory Capital Management, opening a new position worth an estimated $27.9M. The largest seller was Baker Bros. Advisors, cutting an estimated $32.4M.

  • 138 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2021, up from 127 in Q1 2021.
  • Funds reported $2.15B of Protagonist Therapeutics stock for Q2 2021, up 88% quarter-over-quarter.
  • 26 funds opened new Protagonist Therapeutics positions in Q2 2021 and 15 closed out, a net change of +11 holders.
  • The largest Protagonist Therapeutics buyer in Q2 2021 was Victory Capital Management, an estimated $27.9M added.
  • The largest Protagonist Therapeutics seller in Q2 2021 was Baker Bros. Advisors, an estimated $32.4M sold.

Based on aggregated 13F filings for Q2 2021.